The prevalence and mechanisms of hypercalcaemia were studied in a series of patients attending a regional referral centre for rheumatic diseases. In a prospective study one case of hypercalcaemia due to primary hyperparathyroidism was found in 251 consecutive patients who were screened over a three month period. In a retrospective study of 39 patients who had been discovered to be hypercalcaemic during the preceding 12 months known cases of hypercalcaemia were found in 38 (97%) cases. Primary hyperparathyroidism was the most common cause (n=24; 62%), followed by thiazide treatment in five (13%), cancer in three (8%), immobility in three (8%), vitamin D toxicity in two (5%), and chronic liver disease in one (3%). In one case the diagnosis remained unclear after full investigation.
In the 1970s Kennedy and his colleagues presented data to suggest that hypercalcaemia and other biochemical abnormalities suggestive of parathyroid overactivity were a common feature of rheumatoid arthritis.' 2 Detailed investigation of these patients showed low serum immunoreactive parathyroid hormone (PTH) values,' leading the authors to suggest that the hypercalcaemia might have been due to systemic release of a non-PTH bone resorbing factor as part of the disease process. 2 In support of this hypothesis further studies showed significant bone resorbing activity in the serum samples of hypercalcaemic but not normocalcaemic patients with rheumatoid arthritis (RA) . ' Although hypercalcaemia in RA has rarely been described in association with increased extrarenal synthesis of 1,25-dihydroxyvitamin D,4 the high prevalence of hypercalcaemia found by Kennedy' 2 has not been confirmed by other workers.5 6 Accordingly, the nature of the putative bone resorbing factor responsible for the hypercalcaemia in Kennedy's patients has remained unclear.
In view of these conflicting reports we have reassessed both the prevalence and mechanisms of hypercalcaemia in a consecutive series of patients attending a regional referral centre for rheumatic diseases. in 20 patients with RA (range 32-0-117-0 nmol/l GF), 17 with seronegative spondarthritis (28-0-214-0 nmol/l GF), and four patients with osteoarthritis (range 28-0-31-0 nmol/l GF). Subgroup analysis showed no significant difference in any of the above variables when patients were stratified according to use of non-steroidal anti-inflammatory drugs, disease modifying agents (that is, gold, salazopyrine, penicillamine, antimalarial drugs), cytotoxic drugs, or steroids (data not shown). When data from all patients were combined significant correlations were observed between the following variables: serum adjusted calciumandionisedcalcium(r=0'55,p<00001); erythrocyte sedimentation rate (ESR) and serum albumin (r= -0-65, p<0-0001); ESR and serum globulin (r= -0-65, p<0-0001); ESR and urinary hydroxyproline/creatinine ratio (r=0-31, p<0-001); and ESR and serum adjusted calcium (r=0-31, p<0-001).
Discussion
In contrast with Kennedy's observations,' 2 we found only one case of hypercalcaemia in 102 consecutive patients with RA, and on further investigation this patient was found to have primary hyperparathyroidism. Our observations, in combination with those of Scott et al5 and Bramble et al,6 suggest that hypercalcaemia is seldom a feature of uncomplicated RA itself and indicate that the high prevalence of hypercalcaemia in Kennedy's patients was probably due to selection bias in the relatively small number who were studied.
Even if one accepts this to be the case, however, there remains the problem of explain-ing the mechanism of hypercalcaemia in the 7/50 (14%) of Kennedy's patients whose serum calcium values remained raised over a six month period.2 A review of the original data from this study shows that PTH values in the hypercalcaemic patients were generally low to normal, and on this basis primary hyperparathyroidism was excluded. It is now recognised, however, that the poor sensitivity of the PTH assays then available do not permit such an assumption. 12 Indeed, the finding of a detectable PTH value under these circumstances may be interpreted as 'inappropriate', suggestive of primary hyperparathyroidism. 12 In recent years PTH-like biochemical abnormalities have been described in patients with cancer, where the tumour releases a PTH related peptide which binds to the PTH receptor but is not recognised by standard PTH antisera. 13 These patients can be identified biochemically by the findings of hypercalcaemia, increased nephrogenous cAMP excretion (an index of PTH-like bioactivity), and suppressed serum immunoreactive PTH concentrations. 13 Biochemical abnormalities similar to these were found in only one hypercalcaemic patient in our study. Although PTH related peptide release would be a plausible explanation for the hypercalcaemia in this patient, primary hyperparathyroidism could not be completely ruled out because of the relative insensitivity of our assay at low PTH concentrations.
We cannot readily explain the raised nephrogenous cAMP values which were noted in many of the normocalcaemic patients with inflammatory and degenerative arthritis, but they seemed to be an isolated abnormality in the absence of other biochemical evidence of PTH-like activity. At present the reason for this is unclear, but stress induced release of PTH (and hence nephrogenous cAMP) is possible. '4 As in the general population, the commonest cause of hypercalcaemia in our patients was primary hyperparathyroidism.'5 16 Although hypercalcaemia was more commonly associated with RA than other rheumatological conditions, this simply reflects the fact that most (65%) patients attending the centre suffer from this disease. These figures give an approximate prevalence of 24 cases of primary hyperparathyroidism per 3250 patients with RA-that is, 1:135. Although this is more than one order of magnitude higher than that in the general population (approx 1:5000),15 16 revisited. 
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